公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2021 | Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE | Mamounas E. P.; Untch M.; Mano M. S.; CHIUN-SHENG HUANG ; Geyer C. E.; von Minckwitz G.; Wolmark N.; Pivot X.; Kuemmel S.; DiGiovanna M.P.; Kaufman B.; Kunz G.; Conlin A.K.; Alcedo J.C.; Kuehn T.; Wapnir I.; Fontana A.; Hackmann J.; Polikoff J.; Saghatchian M.; Brufsky A.; Yang Y.; Zimovjanova M.; Boulet T.; Liu H.; Tesarowski D.; Lam L.H.; Song C.; Smitt M.; Loibl S. | Annals of oncology : official journal of the European Society for Medical Oncology | 57 | 49 | |
2020 | Patient-reported outcomes from KATHERINE: A phase 3 study of adjuvant trastuzumab emtansine versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for human epidermal growth factor receptor 2–positive breast cancer | Conte P.; Schneeweiss A.; Loibl S.; Mamounas E.P.; von Minckwitz G.; Mano M.S.; Untch M.; CHIUN-SHENG HUANG ; Wolmark N.; Rastogi P.; D’Hondt V.; Redondo A.; Stamatovic L.; Bonnefoi H.; Castro-Salguero H.; Fischer H.H.; Wahl T.; Song C.; Boulet T.; Trask P.; Geyer C.E.; Jr. | Cancer | 16 | 12 | |
2019 | Trastuzumab emtansine for residual invasive HER2-positive breast cancer | Von Minckwitz G.; CHIUN-SHENG HUANG ; Mano M.S.; Loibl S.; Mamounas E.P.; Untch M.; Wolmark N.; Rastogi P.; Schneeweiss A.; Redondo A.; Fischer H.H.; Jacot W.; Conlin A.K.; Arce-Salinas C.; Wapnir I.L.; Jackisch C.; DiGiovanna M.P.; Fasching P.A.; Crown J.P.; W?lfing P.; Shao Z.; Caremoli E.R.; Wu H.; Lam L.H.; Tesarowski D.; Smitt M.; Douthwaite H.; Singel S.M.; Geyer C.E.; Jr. | New England Journal of Medicine | 1510 | 1351 |